Biotechnology News and Research

RSS

Insilico Medicine presents experimentally validated model for drug discovery at NeurIPS 2019

Insilico Medicine, a biotechnology company developing an end-to-end drug discovery pipeline utilizing next-generation artificial intelligence, is proud to present its paper "A Prior of a Googol Gaussians: a Tensor Ring Induced Prior for Generative Models" at the 33rd Conference on Neural Information Processing Systems (NeurIPS).

16 Oct 2019

New initiative aims to use artificial intelligence to identify early drug candidates

Insilico Medicine, in collaboration with ChemDiv, Inc., launched a drug discovery initiative that aims to use the power of artificial intelligence for screening chemistry space with newly designed compounds.

16 Oct 2019

Scientists develop more accurate method to find good targets for cancer immunotherapy

Ludwig Cancer Research scientists have developed a new and more accurate method to identify the molecular signs of cancer likely to be presented to helper T cells, which stimulate and orchestrate the immune response to tumors and infectious agents.

15 Oct 2019

Simpler and direct method for producing lipidated proteins

Some of the body's proteins are not just made up of amino acids, they are also 'decorated' with lipid chains, which significantly influence the biological functions of the protein.

15 Oct 2019

Advances in translational genetics unlocked by Bio-Rad technologies to be presented at ASHG 2019

Scientists will present 24 abstracts and three talks, highlighting research driven in part by Bio-Rad Laboratories' Droplet Digital PCR and single-cell ATAC-Seq (scATAC-Seq) technologies, at the 2019 American Society of Human Genetics Annual Meeting in Houston, October 15-19.

15 Oct 2019

Ludwig scientists develop robust method to refine personalized cancer immunotherapy

14 Oct 2019

Femtogenix announces efficacy, toxicity data of new DNA-binding ADC payload molecules

Femtogenix Ltd, a UK biotechnology company developing the next generation of DNA-interactive Antibody Drug Conjugate (ADC) payloads, today announced data verifying the favorable toxicity profile and potent efficacy of its Pyridinobenzodiazepine (PDD) ADC payload platform in tumor cell models.

14 Oct 2019

Impress your boss with this course

In this webinar, Dr. Michael W. Dong, Pittcon Short Course Instructor, will review best practices, short cuts, and tricks-of-the-trade to help pharmaceutical and other scientists to become more successful in developing effective HPLC methods (potency and ICH-compliant stability-indicating assays) using method templates and universal generic gradient methods.

From Pittcon 14 Oct 2019

Chewing gum to track fertility: Ovulaid

Infertility is a very potent cause of frustration and psychological problems such as anxiety and depression, as well as of high stress. Infertility or subfertility is defined by the World Health Organization as unsuccessful attempts to conceive for five or more years.

10 Oct 2019

A Lego-like approach to enhance nature's own ability to attack bacteria

The Centers for Disease Control and Prevention considers antibiotic resistance one of the most urgent public health threats, one that affects communities worldwide. The ramifications of bacteria's ability to become resistant to antibiotics can be seen in hospitals, public places, our food supply, and our water.

10 Oct 2019

Insilico and CTFH team up to expedite first-in-class therapeutics using AI platform

Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd..

9 Oct 2019

Research provides evidence to support expansion of insurance coverage of NIPT

Research conducted by the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences provides evidence to support expansion of insurance plan coverage of noninvasive prenatal testing (NIPT), a simple maternal blood draw which screens for fetal chromosomal disorders including trisomy 13 (Patau syndrome), trisomy 18 (Edwards syndrome), and trisomy 21 (Down syndrome), to women under the age of 35.

8 Oct 2019

New grants support research on mechanics of tumor cells

At the cellular level, cancer can be viewed as a mechanical engineering challenge. The disease alters the structure and function of cells and tissues, which are meant to perform very specific tasks.

8 Oct 2019

GW researchers to study the underlying pathophysiology of myasthenia gravis

The National Institutes of Health awarded a research team at the George Washington University $7.8 million to establish a rare disease network for myasthenia gravis. The network, which will be part of 25 established NIH Rare Diseases Clinical Research Networks, will include basic and clinical investigators, patient advocacy groups, and biotechnology and pharmaceutical companies working together to enhance therapeutic development for this rare disease.

4 Oct 2019

UCR biochemist receives grant to develop novel lead compound to treat breast cancer

A biochemist at the University of California, Riverside, has received a grant from the Congressionally Directed Medical Research Programs, or CDMRP, of the U.S. Department of Defense to develop a novel lead compound to treat breast cancer, the second most commonly diagnosed cancer among American women.

3 Oct 2019

Adding local anesthetics can improve treatment for incurable breast cancer, melanoma

A new study examined the effects of local anesthetics combined with standard chemotherapy for treatment of incurable triple-negative breast cancer, as well as melanoma.

3 Oct 2019

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Entos Pharmaceuticals Inc. ("Entos" or the "Company"), a healthcare biotechnology company focused on the development of next-generation nucleic acid-based therapies using their Fusogenix drug delivery platform, today announced it has entered into a research, development and collaboration agreement ("Agreement") with a clinical stage biopharmaceutical company ("Partner") focused on the development of novel therapeutic compounds targeting autoimmune and inflammatory diseases.

3 Oct 2019

Horizon Discovery announces full commercial licensing of GS knockout CHO K1 cell line to Glenmark

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced the full commercial licensing to Glenmark Pharmaceuticals, a global innovative pharmaceutical company, of its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line. Terms of the agreement were based on stringent evaluation of the cell line by Glenmark to assess its suitability for adoption into the Company’s biomanufacturing processes.

From Revvity 30 Sep 2019

Optoceutics technique opens up new horizons for regenerative medicine

Using light to facilitate the formation of new blood vessels: it is the breakthrough outcome of a research study carried out by researchers at Istituto Italiano di Tecnologia in Milan (Italy). The study was published in Science Advances.

30 Sep 2019

New method can improve precision medicine, safety of drug-delivery devices

Researchers at the National Institute of Standards and Technology (NIST) have developed an optical system that accurately measures the flow of extraordinarily tiny amounts of liquids -- as small as 10 billionths of a liter (nanoliters) per minute.

27 Sep 2019

Biotechnology News and Research

Insilico Medicine presents experimentally validated model for drug discovery at NeurIPS 2019

New initiative aims to use artificial intelligence to identify early drug candidates

Scientists develop more accurate method to find good targets for cancer immunotherapy

Simpler and direct method for producing lipidated proteins

Advances in translational genetics unlocked by Bio-Rad technologies to be presented at ASHG 2019

Ludwig scientists develop robust method to refine personalized cancer immunotherapy

Femtogenix announces efficacy, toxicity data of new DNA-binding ADC payload molecules

Impress your boss with this course

Chewing gum to track fertility: Ovulaid

A Lego-like approach to enhance nature's own ability to attack bacteria

Insilico and CTFH team up to expedite first-in-class therapeutics using AI platform

Research provides evidence to support expansion of insurance coverage of NIPT

New grants support research on mechanics of tumor cells

GW researchers to study the underlying pathophysiology of myasthenia gravis

UCR biochemist receives grant to develop novel lead compound to treat breast cancer

Adding local anesthetics can improve treatment for incurable breast cancer, melanoma

Entos Pharmaceuticals signs new collaboration agreement with biopharmaceutical company

Horizon Discovery announces full commercial licensing of GS knockout CHO K1 cell line to Glenmark

Optoceutics technique opens up new horizons for regenerative medicine

New method can improve precision medicine, safety of drug-delivery devices

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News